PrEP Biopharm Ltd

PrEP Biopharm Ltd.

PrEP Biopharm is a development stage biopharmaceutical company that is creating a fundamentally new paradigm of prophylaxis for upper respiratory tract infections.

PrEP Biopharm Limited was spun out of Janssen (a Johnson & Johnson company) in 2015 with a worldwide exclusive license of PrEP 001. In November 2015 hVIVO acquired a significant equity stake in PrEP Biopharm.

Prior to this, in 2014 hVIVO conducted a proof of concept study for Janssen which demonstrated that their compound, now named PrEP-001, achieved a threefold reduction in clinical illness and an eightfold reduction in common cold symptoms compared with a placebo. With these promising results, hVIVO saw tremendous commercial potential for PrEP-001.

To learn more visit the PrEP Biopharm Ltd website here.

Contact Us

If you are interested to find out more about these and other hVIVO developments and innovations, and how there may be a collaborative or partnering opportunity with your organisation, then please use the “Contact Us” form on this website.